Is Inovio Pharmaceuticals (INO) a High-Stakes Bet Ahead of its October PDUFA Date

Related Articles

What Does the FDA's PDUFA Extension Signal for Rhythm Pharmaceuticals

6 months ago

Texas Instruments' Tactical Bounce: A High-Stakes Bet on Analog and AI Ahead of Earnings

2 months ago

Why is OPTT's Upcoming Earnings Report a High-Stakes Bet

6 months ago

Western Union's High Yield Hides a High-Stakes Digital Transformation

2 months ago

Category

You may also like

Stock News•1 week ago

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

Inovio's INO-3107 BLA for recurrent respiratory papillomatosis remains under FDA review with an Oct. 30 PDUFA date, keeping a binary regulatory catalyst on the calendar.

INO

Share

Stock News•2 weeks ago

Bet on 5 Top-Ranked Stocks With Rising P/E

Five stocks—CURI, INO, GDS, NMG, and CCOI—show rising P/E ratios, signaling potential momentum. Investors may consider this unconventional approach, though no specific magnitude or catalyst is provide...

CCOI

Share

Stock News•1 months ago

Do Options Traders Know Something About Agenus Stock We Don't?

Agenus (AGEN) stock saw unusual options activity, which could signal large investors positioning for a move. The trigger is elevated call or put volume relative to open interest.

AGEN

Share